axicorp GmbH, headquartered in Germany, is a prominent player in the pharmaceutical and healthcare industry, specialising in the development and distribution of innovative medicinal products. Founded in 2007, the company has established a strong presence across Europe, focusing on key operational regions that include Germany, Austria, and Switzerland. With a commitment to quality and efficacy, axicorp GmbH offers a diverse portfolio of prescription and over-the-counter medications, as well as healthcare solutions tailored to meet the needs of patients and healthcare professionals. Their unique approach combines advanced research with a deep understanding of market demands, positioning them as a trusted partner in the healthcare sector. Notable achievements include a robust pipeline of products that address critical health challenges, solidifying their reputation as a leader in the pharmaceutical landscape.
How does axicorp GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Real Estate Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
axicorp GmbH's score of 17 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
axicorp GmbH, headquartered in Germany, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Dermapharm Holding SE, which may influence its climate commitments and reporting practices. As of now, axicorp GmbH has not established any documented reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. This lack of specific commitments suggests that the company may still be in the early stages of developing a comprehensive climate strategy. Given the absence of direct emissions data and reduction targets, it is essential for axicorp GmbH to consider implementing robust climate action plans to align with industry standards and expectations. This could include setting measurable targets for reducing greenhouse gas emissions across all scopes, particularly as part of its corporate family relationship with Dermapharm Holding SE, which may have its own climate initiatives and reporting frameworks.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
axicorp GmbH has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.